NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
- Authors: Semiglazov V.F1, Semiglazov V.V2, Dashyan G.A1, Krivorotko P.V1, Nikolaev K.S1, Semiglazova T.Y.1, Komyakhov A.V2, Bessonov A.A1, Donskikh R.V1, Paltuev R.M1, Zernov K.Y.1
-
Affiliations:
- FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH
- St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPH
- Issue: No 8 (2016)
- Pages: 14-16
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288907
- ID: 288907
Cite item
Open Access
Access granted
Abstract
Keywords
Full Text
About the authors
V. F Semiglazov
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH
Email: vsemiglazov@mail.iu
MD, Prof., Honored Scientist, Corresponding Member of RAS, Head of the Scientific Department of Bieast Tumors, Chief Researcher St.-Petersburg
V. V Semiglazov
St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPHSt.-Petersburg
G. A Dashyan
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
P. V Krivorotko
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
K. S Nikolaev
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
T. Yu Semiglazova
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
A. V Komyakhov
St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPHSt.-Petersburg
A. A Bessonov
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
R. V Donskikh
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
R. M Paltuev
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
K. Yu Zernov
FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPHSt.-Petersburg
References
- Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы: биология, местное и системное лечение. М, 2014. 352 с.
- Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., Swain S.M., Prowell T., Loibl S., Wickerham D.L., Bogaerts J., Baselga J., Perou C., Blumenthal G., Blohmer J., Mamounas E.P., Bergh J., Semiglazov V., Justice R., Eidtmann H., Paik S., Piccart M.,Sridhara R., Fasching P.A., Slaets L., Tang S., Gerber B., Geyer C.E. Jr, Pazdur R., Ditsch N., Rastogi P., Eiermann W., von Minckwitz G. Pathological complete response and long term clinical benefit in breast cancer: the CTNEOBC pooled analysis. Lancet. 2014;384: 164-72.
- Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., Margolese R.G., Hoehn J.L., Vogel V.G., Dakhil S.R., Tamkus D., King K.M.,PajonE.R, WrightM.J.,RobertJ.,PaikS, Mamounas E.P., Wolmark N. Preoperative chemotherapy updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J. Clin. Oncol. 2008;26:778-85.
- Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Cli-ment M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375:377-84.
- Semiglazov V., Eiermann W., Zambetti M., Manikhas A., Bozhok A., Lluch A., Tjulandin S., Sabadell M.D., Caballero A., Valagussa P., Baselga J., Gianni L. Surgery following neoadjuvant therapy in patients with HER2 - positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 2011;37(10):856-63.
- Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., Pedrini J.L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13:25-32.
- U.S. Food and Drug Administration. FDA approves Perjeta for neoadjuvant breast cancer treatment. http://www. fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm370393. htm. Accessed March 3, 2015.
- Gradishar W.J., Anderson B.O., Blair S.L., Burstein H.J., Cyr A., Elias A.D., Farrar W.B., Forero A., Giordano S.H., Goldstein L.J., Hayes D.F., Hudis C.A., Isakoff S.J., Ljung B.M., Marcom P.K., Mayer I.A., McCormick B., Miller R.S., Pegram M., Pierce L.J., Reed E.C., Salerno K.E., Schwartzberg L.S., Smith M.L., Soliman H., Somlo G., Ward J.H., Wolff A.C., Zellars R., Shead D.A., Kumar R.; National Comprehensive Cancer Network Breast Cancer Panel. Breast Cancer Version 3. J. Natl. Compr. Canc. Netw. 2015;13(4):448-75.
Supplementary files
